Our data indicate that MassARRAY-based multiplex genetic testing both for somatic mutations and for ALK, ROS1, and RET fusion genes performed well with nucleic acid (DNA and RNA) extracted from FFPE tumor specimens obtained from patients with advanced NSCLC. This evidence concerns the gene ROS1 and neoplasm.